Hint mode is switched on Switch off

Sangamo Therapeutics, ordinary share
SGMO, US8006771062

Add a stock to WL
Choose all Reset all
Sangamo Therapeutics, сountry — USA
No trading data
Data display in a chart | table
Source of information - PJSC "MOEX". Further disctribution of MOEX information is prohibited without prior consent with PJSC "MOEX".
Source of information - PJSC "MOEX". Further disctribution of MOEX information is prohibited without prior consent with PJSC "MOEX".
No data
from
to
ADD-IN
Cbonds add-in API
bond data api
Authorization required
You need to request access
More than 2,500 records have been found, please specify your request
No data for the selected period

Upgrade to Premium features

Cbonds consolidates global bond, stock, ETF and indices data into a single platform — so you can analyze faster, make informed investment decisions and outperform the market

Get access
Welcome to Cbonds

  • Full access to the largest bond database

    Bond parameters,
    prospectuses

  • Seamless
    Data export

    Analyze the data in the most efficient way

  • Bond pricing

    Current & historical quotes from 400+ stock exchanges & OTC market

  • Smart risk assessment

    Credit ratings, financial reports

Get access

Latest quotes

Get access to the largest financial database

Try in 7-days Demo access

Free for company representative

  • Evaluate advanced analytical tools
  • Get full online access to the database
  • Try our powerful bond screener
  • Track bond prices from 400+ sources

Get access to the largest financial database

Representative of the company 7 days FREE trial

Professional access to the data

Private investor

Individual access

Issuer

Profile
Sangamo Therapeutics, Inc. focuses on translating ground-breaking science into genomic therapies that transform patients' lives using platform technologies in genome editing, gene therapy, gene regulation, and cell therapy.
  • Issuer
  • Full borrower / issuer name
    Sangamo Therapeutics, Inc.
  • Industry
    Pharmaceutical Preparation and Biotechnology

Placement data

  • Placement type
    IPO | Finished
  • Subscription type
    Open
  • Placement exchange
    NASDAQ
  • Ticker
    SGMO
  • Placement
    06.04.2000
  • Lock up period
    180
  • Number of papers
    3,500,000
  • Volume of raised funds
    52.5 mln USD
  • Placement share
    16%
  • Final placement price
    15 USD
  • Price change since placement date
    -98.85%
  • By capitalization
    312.81 mln USD
  • Placement type
    SPO | Finished
  • Subscription type
    Open
  • Placement exchange
    NASDAQ
  • Ticker
    SGMO
  • Placement
    22.06.2017
  • Lock up period
    180
  • Number of papers
    10,000,000
  • Volume of raised funds
    72.5 mln USD
  • Placement share
    12.23%
  • Final placement price
    7.25 USD
  • Price change since placement date
    -97.63%
  • By capitalization
    592.7 mln USD
  • Placement type
    SPO | Finished
  • Subscription type
    Open
  • Placement exchange
    NASDAQ
  • Ticker
    SGMO
  • Placement
    24.04.2018
  • Lock up period
    180
  • Number of papers
    11,019,284
  • Volume of raised funds
    200 mln USD
  • Final placement price
    18.15 USD
  • Price change since placement date
    -99.05%
  • Placement type
    SPO | Finished
  • Subscription type
    Open
  • Placement exchange
    NASDAQ
  • Ticker
    SGMO
  • Placement
    13.05.2025
  • Lock up period
    180
  • Number of papers
    12,235,000
  • Volume of raised funds
    6.12 mln USD
  • Placement share
    5.15%
  • Final placement price
    0.5 USD
  • Price change since placement date
    -65.6%
  • By capitalization
    118.8 mln USD
Other placements of the issuer Hide

IFRS/US GAAP reports

2025
I q eng
IV q eng
2024
I q eng
II q eng
III q eng
IV q eng
2023
I q eng
II q eng
III q eng
IV q eng
2022
I q eng
II q eng
III q eng
IV q eng
2021
I q eng
II q eng
III q eng
IV q eng
2020
I q eng
II q eng
III q eng
IV q eng
2019
I q eng
II q eng
III q eng
IV q eng
2018
I q eng
II q eng
III q eng
IV q eng
2017
I q eng
II q eng
III q eng
IV q eng
2016
I q eng
II q eng
III q eng
IV q eng
2015
I q eng
II q eng
III q eng
IV q eng
2014
IV q eng
Show all Hide

Indicators

News

03/02/2026 Sangamo Therapeutics: Entry Into A Material Definitive Agreement, Unregistered Sales Of Equity Securities, Financial Statements And Exhibits
02/02/2026 Sangamo Therapeutics: Results Of Operations And Financial Condition, Departure Of Directors Or Certain Officers; Election Of Directors; Appointment Of Certain Officers; Compensatory Arrangements Of Certain Officers
09/09/2025 Sangamo Therapeutics: Departure Of Directors Or Certain Officers; Election Of Directors; Appointment Of Certain Officers; Compensatory Arrangements Of Certain Officers
07/08/2025 Sangamo Therapeutics: And In The Press Release Furnished As Exhibit 99.1 To This Current Report On Form 8k Shall Not Be Deemed “filed” For Purposes Of Section 18 Of The Securities Exchange Act Of 1934, As Amended, Or Otherwise Subject To The Liabilities Of That Section Or Sections 11 And 12(a)(2) Of The Securities Act Of 1933, As Amended. The Information Contained In This Item 2.02 And In The Press Release Furnished As Exhibit 99.1 To This Current Report On Form 8k Shall Not Be Incorporated By Reference Into Any Filing With The Securities And Exchange Commission Made By Sangamo Whether Made Before Or After The Date Hereof, Regardless Of Any General Incorporation Language In Such Filing, Financial Statements And Exhibits
12/06/2025 Sangamo Therapeutics: Departure Of Directors Or Certain Officers; Election Of Directors; Appointment Of Certain Officers; Compensatory Arrangements Of Certain Officers, Submission Of Matters To A Vote Of Security Holders, Financial Statements And Exhibits
All organization news

Holders

Industry Leaders

Registration is required to get access.